Armata Pharmaceuticals, Inc.
(NYSE Amex Equities : ARMP)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -4.90%58.570.0%$919.92m
AMGNAmgen, Inc. 1.22%258.241.3%$759.50m
GILDGilead Sciences, Inc. 0.38%76.351.0%$735.36m
REGNRegeneron Pharmaceuticals, Inc. 2.18%622.452.5%$672.88m
NVAXNovavax, Inc. 2.43%81.64102.0%$616.96m
BIIBBiogen, Inc. 0.13%265.121.6%$544.40m
VRTXVertex Pharmaceuticals, Inc. 1.68%291.101.9%$526.40m
ILMNIllumina, Inc. 1.24%373.103.5%$309.63m
ALXNAlexion Pharmaceuticals, Inc. -0.08%112.302.0%$225.16m
BMRNBioMarin Pharmaceutical, Inc. 0.75%126.784.3%$216.16m
SGENSeattle Genetics, Inc. 0.90%169.036.1%$202.76m
SRNESorrento Therapeutics, Inc. -1.15%6.851.8%$187.20m
SRPTSarepta Therapeutics, Inc. -1.77%162.7513.9%$164.07m
INCYIncyte Corp. 3.72%106.472.5%$163.74m
IMMUImmunomedics, Inc. 1.71%37.5413.3%$157.98m

Company Profile

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.